Biomarkers in Cervical Cancer

Cervical cancer is the fourth most common gynecologic malignancy worldwide with an estimated incidence of approximately 570000 cases worldwide in 2018. Despite the advances that were made in the primary and secondary prevention strategies the last decades, its actual prevalence seems to reach a negative plateau which is attributed to the limited acceptance of vaccination as well as the resources that are available in several low income countries. In the present article we review novel biomarkers that seem to interfere in the pathophysiology of the disease and can, thus, be used as tools for the early identification of patients at risk as well as biomarkers of disease response to the various treatment strategies.